Investigating the Role of Tumor-Infiltrating Lymphocytes as Predictors of Lymph Node Metastasis in Deep Submucosal Invasive Colorectal Cancer: A Retrospective Cross-Sectional Study.
colorectal cancer
lymph node metastasis
tumor microenvironment
tumor-infiltrating T cells
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
18
08
2023
revised:
25
09
2023
accepted:
30
10
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
The role of tumor-infiltrating T cells (TILs) in colorectal cancer (CRC) and their significance in early-stage CRC remain unknown. We investigated the role of TILs in early-stage CRC, particularly in deep submucosal invasive (T1b) CRC. Sixty patients with CRC (20 each with intramucosal [IM group], submucosal invasive [SM group], and advanced cancer [AD group]) were randomly selected. We examined changes in TILs with tumor invasion and the relationship between TILs and LN metastasis risk. Eighty-four patients with T1b CRC who underwent initial surgical resection with LN dissection or additional surgical resection with LN dissection after endoscopic resection were then selected. TIL phenotype and number were evaluated using triple immunofluorescence for CD4, CD8, and Foxp3. All subtypes were more numerous according to the degree of CRC invasion and more abundant at the invasive front of the tumor (IF) than in the center of the tumor (CT) in the SM and AD groups. The increased Foxp3 cells at the IF and high ratios of Foxp3/CD4 and Foxp3/CD8 positively correlated with LN metastasis. In conclusion, tumor invasion positively correlated with the number of TILs in CRC. The number and ratio of Foxp3 cells at the IF may predict LN metastasis in T1b CRC.
Identifiants
pubmed: 37958412
pii: cancers15215238
doi: 10.3390/cancers15215238
pmc: PMC10649548
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Gastroenterol. 2004 Jun;39(6):534-43
pubmed: 15235870
J Immunother. 2010 May;33(4):435-41
pubmed: 20386463
J Leukoc Biol. 2008 Sep;84(3):623-30
pubmed: 18467655
Int J Clin Oncol. 2020 Jan;25(1):1-42
pubmed: 31203527
J Leukoc Biol. 2009 Nov;86(5):1065-73
pubmed: 19741157
Immunol Lett. 2011 Jul;138(1):19-21
pubmed: 21333682
Front Biosci. 2008 May 01;13:6255-68
pubmed: 18508658
BMC Cancer. 2022 Jun 2;22(1):601
pubmed: 35655158
Cancer Sci. 2022 Jun;113(6):1939-1954
pubmed: 35377522
Cancer Sci. 2021 Jul;112(7):2692-2704
pubmed: 33964093
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S414-21
pubmed: 24566864
Cancer. 2008 Sep 15;113(6):1387-95
pubmed: 18671239
J Histochem Cytochem. 2021 Apr;69(4):271-286
pubmed: 33550891
Breast Cancer Res. 2015 Sep 04;17:124
pubmed: 26341640
J Neuroimmunol. 2007 Dec;192(1-2):68-78
pubmed: 18006080
Gastroenterology. 2004 Aug;127(2):385-94
pubmed: 15300569
Ann Surg Oncol. 2020 Jun;27(6):2102-2109
pubmed: 31773516
Oncol Rep. 2000 Jul-Aug;7(4):783-8
pubmed: 10854544
Gastroenterology. 2007 Jun;132(7):2328-39
pubmed: 17570208
PLoS One. 2013;8(1):e53630
pubmed: 23382847
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Cancers (Basel). 2020 Jul 14;12(7):
pubmed: 32674255
J Gastroenterol Hepatol. 2012 Jun;27(6):1057-62
pubmed: 22142484
J Gastroenterol. 1995 Dec;30(6):710-7
pubmed: 8963387
Eur J Cancer. 2014 Jan;50(2):309-19
pubmed: 24103145
Front Immunol. 2022 Jan 24;13:781222
pubmed: 35140715
Ann Surg Oncol. 2016 Mar;23(3):826-32
pubmed: 26581202
Sci Rep. 2020 Feb 25;10(1):3360
pubmed: 32099066
Br J Cancer. 2014 May 13;110(10):2551-9
pubmed: 24675384
Acta Oncol. 2013 Jan;52(1):73-81
pubmed: 23075422
Strahlenther Onkol. 2020 May;196(5):465-473
pubmed: 31828392
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Br J Cancer. 2006 Jan 30;94(2):275-80
pubmed: 16421594